Working… Menu
Trial record 1 of 1 for:    NCT02872259
Previous Study | Return to List | Next Study

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02872259
Recruitment Status : Recruiting
First Posted : August 19, 2016
Last Update Posted : August 22, 2019
BerGenBio ASA
Information provided by (Responsible Party):
Haukeland University Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 1, 2023